Clinical implications of discrepant results between genotypic MTBDRplus and phenotypic Löwenstein-Jensen method for isoniazid or rifampicin drug susceptibility tests in tuberculosis patients | Zendy

Ji Young Kang | Zendy; Jung Hur | Zendy; Shin-Young Kim | Zendy; Sanghoon Jeon | Zendy; Jaeha Lee | Zendy; Youn Jeong Kim | Zendy; Seok Chan Kim | Zendy; Yeon Joon Park | Zendy; Young Kyoon Kim | Zendy; Hwa Sik Moon | Zendy

Open Access

Clinical implications of discrepant results between genotypic MTBDRplus and phenotypic Löwenstein-Jensen method for isoniazid or rifampicin drug susceptibility tests in tuberculosis patients

Author(s) -

Ji Young Kang,

Jung Hur,

Shin-Young Kim,

Sanghoon Jeon,

Jaeha Lee,

Youn Jeong Kim,

Seok Chan Kim,

Yeon Joon Park,

Young Kyoon Kim,

Hwa Sik Moon

Publication year - 2019

Publication title -

journal of thoracic disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.682

H-Index - 60

eISSN - 2077-6624

pISSN - 2072-1439

DOI - 10.21037/jtd.2019.01.58

Subject(s) - isoniazid , medicine , genotype , rifampicin , tuberculosis , drug resistance , rifabutin , pathology , genetics , biology , clarithromycin , gene , helicobacter pylori

The widespread use of molecular, genotypic drug susceptibility tests (DSTs) for antituberculosis (anti-TB) drugs has led to the dilemma of interpreting discordant results between genotypic and conventional, phenotypic DSTs. We investigated the clinical characteristics, including treatment patterns and outcomes, of TB patients with a genotype-phenotype discrepancy in susceptibility to isoniazid (INH) or rifampicin (RIF).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research